NCT06238648View on ClinicalTrials.gov

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2030

Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo PET/CT and/or CT

BIOLOGICAL

Epcoritamab

Given SC

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Patient Observation

Undergo observation

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (6)

10065

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

27599

NOT_YET_RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

55905

NOT_YET_RECRUITING

Mayo Clinic in Rochester, Rochester

63110

NOT_YET_RECRUITING

Siteman Cancer Center at Washington University, St Louis

84112

RECRUITING

Huntsman Cancer Institute/University of Utah, Salt Lake City

07601

NOT_YET_RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER